# R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

> **NCT04214626** · PHASE2 · COMPLETED · sponsor: **Henan Cancer Hospital** · enrollment: 60 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Lenalidomide
- **DRUG:** Cyclophosphamide
- **DRUG:** Epirubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT04214626
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-05
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-04-19
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04214626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04214626, "R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04214626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*